Benzo[a]pyrene-enhanced mutagenesis by asbestos in the lung of lambda-lacI transgenic rats.
To study the suspected mechanism of the interaction between tobacco smoking and asbestos exposure in the modulation of cancer risk, the mutagenic potential of asbestos in combination with the tobacco smoke carcinogen benzo[a]pyrene (B[a]P) was examined in vivo in the rat lung. B[a]P was administered intratracheally in one set of experiments, or by two daily intraperitoneal injections in another set of experiments, to lambdalacI transgenic rats, together with 1, 2 or 4 x 2 mg amosite in one experiment. In the first experiment, the combined action of amosite and B[a]P caused a synergistic (superadditive) increase of mutation frequency in the lung, as compared to groups treated only with asbestos or B[a]P. In the second experiment, i.p. treatment with B[a]P did not significantly alter the mutation frequency induced by amosite, neither after 4 nor after 16 weeks of exposure. The B[a]P-DNA adduct levels were unaffected by amosite co-treatment in both experiments. We assume that the synergistic increase of mutation frequency after intratracheal treatment was due to the mitogenic activities of B[a]P and of amosite. In conclusion, our findings indicate that a weak and delayed mutagenic effect of amosite in rat lung observed in another study was strongly enhanced by the concomitant action of B[a]P. The striking enhancement effect of B[a]P may provide a basis for understanding the suspected synergism of smoking on asbestos carcinogenesis.
National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, 48, Vassileos Constantinou Ave., Athens 11635, Greece.
P
P
Loli
J
J
Topinka
P
P
Georgiadis
M
M
Dusinská
M
M
Hurbánková
Z
Z
Kováciková
K
K
Volkovová
T
T
Wolff
D
D
Oesterle
S A
SA
Kyrtopoulos
D000818:Animals; D030801:Animals, Genetically Modified; D001194:Asbestos / Q000633:toxicity*; D017639:Asbestos, Amosite / Q000633:toxicity*; D001564:Benzo(a)pyrene / Q000008:administration & dosage / Q000633:toxicity*; D018736:DNA Adducts; D005260:Female; D007322:Instillation, Drug; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D019016:Mineral Fibers / Q000633:toxicity; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D011916:Rats, Inbred F344; D017208:Rats, Wistar; D012097:Repressor Proteins / Q000235:genetics*
D018736:DNA Adducts; D019016:Mineral Fibers; D009153:Mutagens; D012097:Repressor Proteins; D017639:Asbestos, Amosite; D001194:Asbestos; D001564:Benzo(a)pyrene; D008315:Malondialdehyde